Loading…
Eliminating Opioid Related Infectious Diseases Act of 2018
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,805 other S bills in the 115th — cohort avg 41d
Eliminating Opioid Related Infectious Diseases Act of 2018 This bill amends the Public Health Service Act to require the Centers for Disease Control and Prevention to expand its grant program for combating hepatitis C infections to include other infections associated with injection drug use.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2018 · fourth_quarter · Health Issues
Support for H.R. 5353 /S. 2579 - Eliminating Opioid Related Infectious Diseases Act of 2018. Support for H.R. 6 Sec. 7141 - Support for Patients and Communities Act. Pharmaceutical policy as it relates to payments under the 340B program.
Client expense: Not reported · Firm income: $80,000
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Health Issues
Initiatives relating to the Administration's "Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs"; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Support for H.R. 5353/S.2579 - Eliminating Opioid Related Infectious Diseases Act of 2018. FDA safety requirements. Support for H.R. 6 Sec. 7141 - Support for Patients and Communities Act.
Client expense: $680,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2018 · third_quarter · Health Issues
Support for H.R. 5353 /S. 2579 - Eliminating Opioid Related Infectious Diseases Act of 2018. Support for H.R. 6 Sec. 7141 - Support for Patients and Communities Act. Pharmaceutical policy as it relates to payments under the 340B program.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Health Issues
Administration's "Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs"; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV and HIV portfolio. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Support for H.R. 5353/S.2579 - Eliminating Opioid Related Infectious Diseases Act of 2018. FDA safety requirements.
Client expense: $800,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2018 · second_quarter · Health Issues
Support for H.R. 5353 /S. 2579 - Eliminating Opioid Related Infectious Diseases Act of 2018.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Health Issues
Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV and HIV portfolio. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Prison population and hepatitis C. International trade and protection of intellectual property. Support for H.R. 5353/S.2579 - Eliminating Opioid Related Infectious Diseases Act of 2018. FDA safety requirements.
Client expense: $810,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2018 · first_quarter · Health Issues
Support for H.R. 5353/S. 2579 - Eliminating Opioid Related Infectious Diseases Act of 2018.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Democratic |
| IL |